Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Pancreatic Ductal Adenocarcinoma: early-phase trial registry
11 of 21 indexed Metastatic Pancreatic Ductal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 11 currently recruiting · #797 of 28,707 conditions by registered trial count
Metastatic Pancreatic Ductal Adenocarcinoma: 21 US clinical trials tracked, 11 recruiting.
Metastatic Pancreatic Ductal Adenocarcinoma is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-pancreatic-ductal-adenocarcinoma
OPEN 11 | RECR 52% | LATE 1 | EARLY 19 | RANK #797 | SPON 3
Volume-matched condition peers
Nearest open-share peer: End-Stage Kidney Disease (52% recruiting · 21 trials)
Metastatic Pancreatic Ductal Adenocarcinoma lists 11 open slots (52% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Pancreatic Ductal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Pancreatic Ductal Adenocarcinoma is recruiting above its size-band peers.
11 of 21 indexed trials (52.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Pancreatic Ductal Adenocarcinoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 3 of 21 trials (14.3%). 18 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Pancreatic Ductal Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 21 trials that report a genuine target (sentinel values excluded). 15 of those (71.4%) plan for fewer than 100 participants.
-
Metastatic Pancreatic Ductal Adenocarcinoma research is mostly interventional.
20 interventional and 1 observational studies make up this index (95.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines
NCT06445062
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
NCT06989437
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
NCT04005690
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
University of California, San Francisco
NCT06600906
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
NCT06648434
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami
NCT07096362
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT05685602
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
NCT07214298
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology
NCT04150042
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Benjamin Spieler
NCT06843551
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
NCT07089940
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Arcus Biosciences
NCT06608927
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Flemming Forsberg
NCT04821284
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
NCT02600949
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Erasca
NCT05039177
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Agenus
NCT05630183
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
Memorial Sloan Kettering Cancer Center
NCT04666740
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT06168812
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Georgetown University
NCT05558982
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
NCT05642962
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
NCT04493060
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Pancreatic Ductal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Pancreatic Ductal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Pancreatic Ductal Adenocarcinoma page
21 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Metastatic Pancreatic Ductal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Metastatic Pancreatic Ductal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Pancreatic Ductal Adenocarcinoma condition card totals 21 registered trials; most-linked intervention Computed Tomography; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.